Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC
Adagrasib shows durable clinical benefit in previously treated, advanced KRASG12C-mutated non-small cell lung cancer, including patients with brain metastases.
Medscape Medical News
source https://www.medscape.com/viewarticle/975059?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975059?src=rss
Comments
Post a Comment